There are gender differences in the efficacy of immunotherapy and the incidence of autoimmune toxicity observed across different cancer types, for example, men have higher rates of objective response to PD-1/PD-L1 inhibitors in certain tumors, while women tend to experience more severe immune-related adverse events (72). Here, PDCD1 is linked to cancer.